Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 75venetoclax 55Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Podophyllotoxin × Other hematologic neoplasm × Clear all
NCT00540995 2023-11-30

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

City of Hope Medical Center

Phase 1/2 Terminated
25 enrolled 9 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡